VH032
Based on 10 publication(s) in Google Scholar
VH032 is a VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. VH032 is a VHL/HIF-1α interaction inhibitor with a KdPROTACs.
For research use only. We do not sell to patients.
- Purity: 99.43%
- CAS No.: 1448188-62-2
- Formula: C24H32N4O4S
- Molecular Weight:472.60
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Ubiquitination Compound Library
HY-L050
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Anti-Prostate Cancer Compound Library
HY-L124
-
E3 Ligase Ligand Library
HY-L128
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) VH032
More- J Control Release. 2026 May 10:393:114828. [Abstract]
- Chem Sci. 2026 Feb 19. [Abstract]
- J Med Chem. 2024 Mar 14;67(5):3448-3466. [Abstract]
- J Med Chem. 2023 Jun 22;66(12):7926-7942. [Abstract]
- Int Immunopharmacol. 2025 May 14:158:114831. [Abstract]
- Arch Biochem Biophys. 2022 May 30;721:109194. [Abstract]
- Biochem Biophys Rep. 2025 Sep 18:44:102254. [Abstract]
- Res Sq. 2026 Apr 23.
- bioRxiv. 2025 Jul 22.
- bioRxiv. 2025 April 30.
Customer Validation & Images
-
WB
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
Cell Imaging/Staining
Biological Activity
|
VHL |
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1448188-62-2
-
Appearance Solid
-
Molecular Weight 472.60
-
Formula C24H32N4O4S
-
Color White to off-white
-
SMILES
CC(N=CS1)=C1C2=CC=C(CNC([C@@H]3C[C@@H](O)CN3C([C@H](C(C)(C)C)NC(C)=O)=O)=O)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
J Control Release
The HSP90-dependent bioorthogonal PROTAC prodrug system enables tumor-selective and enhanced protein degradation. [Abstract]2026 May 10:393:114828. PMID: 41839264
VH032 purchased from MedChemExpress. Usage Cited in: J Control Release. 2026 May 10:393:114828. [Abstract]
Western blot analysis of BRD4 levels in HeLa cells pretreated with JQ-1 for 6 h or VH032 (1 μM) for 6 h, followed by treatment with HBPROTAC [Tz-PU (2 h pretreatment) + TCO-MZ1] for 8 h.
VH032 purchased from MedChemExpress. Usage Cited in: J Control Release. 2026 May 10:393:114828. [Abstract]
Western blot analysis of Bcl-xL levels in HeLa cells pretreated with MG-132, ABT-263 or VH032 (1 μM) for 6 h, followed by treatment with HBPROTAC [Tz-PU (2 h pretreatment) + TCO-DT2216] for 8 h.
-
Chem Sci
Unveiling BCL-xL-specific PROTAC efficiency and dissociation pathways using native mass spectrometry. [Abstract]2026 Feb 19. PMID: 41727719 -
J Med Chem
Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates. [Abstract]2024 Mar 14;67(5):3448-3466. PMID: 38356330 -
J Med Chem
2023 Jun 22;66(12):7926-7942. PMID: 37267712 -
Int Immunopharmacol
Pomalidomide promotes macrophage control of Mycobacterium tuberculosis via enhancing HDAC6-mediated autophagy. [Abstract]2025 May 14:158:114831. PMID: 40373598 -
Arch Biochem Biophys
Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer. [Abstract]2022 May 30;721:109194. PMID: 35337811
VH032 purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2022 May 30;721:109194. [Abstract]
Western blotting analysis of AR in BT549 cells treated with AR-PROTAC (100 nM), or co-treated with enzalutamide (1 μM), VH032 (1 μM), MLN924 (1 μM), or MG132 (10 μM) for 24 h.
-
Biochem Biophys Rep
2025 Sep 18:44:102254. PMID: 41030787
VH032 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Rep. 2025 Sep 18:44:102254. [Abstract]
VH032 (0-100 μm; 24 h) inhibits the proliferation of U87MG and U251 cells.
VH032 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Rep. 2025 Sep 18:44:102254. [Abstract]
VH032 inhibits the migration and invasion of glioma cells. a. VH032 inhibits the migration of glioma cells in wound healing assay. The migratory capacity of U87MG (treated with 59.2 μM VH032) and U251 (treated with 85.07 μM VH032) cells was evaluated at 0 h and 24 h.
VH032 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Rep. 2025 Sep 18:44:102254. [Abstract]
Transwell assesses were performed using U87MG (59.2 μM VH032) and U251 (85.07 μM VH032) to evaluate the effect of VH032 on glioma cell invasion.
VH032 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Rep. 2025 Sep 18:44:102254. [Abstract]
VH032 induced the apoptosis of glioma cells. Flow cytometry analysis of apoptotic U87MG (59.2 μM VH032) and U251 (85.07 μM VH032) cells via Annexin V-FITC/PI staining after 24 h of treatment. The effect of VH032 on the apoptosis of glioma cells was significantly increased.
VH032 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Rep. 2025 Sep 18:44:102254. [Abstract]
VH032 induced G2/M cell cycle arrest in glioma cells. Flow cytometry analysis of cell cycle distribution in U87MG (59.2 μM VH032) and U251 (85.07 μM VH032) cells after 24 h of treatment, and the proportion of cells in the G2/M phase increased significantly
VH032 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Rep. 2025 Sep 18:44:102254. [Abstract]
VH032 affects cell viability, migration, invasion and apoptosis by inhibiting the VHL/HIF-1α/VEGF signalling pathway. Western blotting analysis of VHL, HIF-1α, and VEGF protein levels in U87MG (59.2 μM VH032) and U251 (85.07 μM VH032) cells after 24 h of treatment.
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (211.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.5 mg/mL (7.41 mM); Clear solution
This protocol yields a clear solution of ≥ 3.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (35.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 3.5 mg/mL (7.41 mM); Clear solution
This protocol yields a clear solution of ≥ 3.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (35.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Michael Zengerle, et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. ACS Chem Biol. 2015 Aug 21;10(8):1770-7. [Content Brief]
[2]. Carles Galdeano, et al. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J Med Chem. 2014 Oct 23;57(20):8657-63. [Content Brief]
[3]. Kwok-Ho Chan, et al. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1160 mL | 10.5798 mL | 21.1595 mL | 52.8989 mL |
| 5 mM | 0.4232 mL | 2.1160 mL | 4.2319 mL | 10.5798 mL | |
| 10 mM | 0.2116 mL | 1.0580 mL | 2.1160 mL | 5.2899 mL | |
| 15 mM | 0.1411 mL | 0.7053 mL | 1.4106 mL | 3.5266 mL | |
| 20 mM | 0.1058 mL | 0.5290 mL | 1.0580 mL | 2.6449 mL | |
| 25 mM | 0.0846 mL | 0.4232 mL | 0.8464 mL | 2.1160 mL | |
| 30 mM | 0.0705 mL | 0.3527 mL | 0.7053 mL | 1.7633 mL | |
| 40 mM | 0.0529 mL | 0.2645 mL | 0.5290 mL | 1.3225 mL | |
| 50 mM | 0.0423 mL | 0.2116 mL | 0.4232 mL | 1.0580 mL | |
| 60 mM | 0.0353 mL | 0.1763 mL | 0.3527 mL | 0.8816 mL | |
| 80 mM | 0.0264 mL | 0.1322 mL | 0.2645 mL | 0.6612 mL | |
| 100 mM | 0.0212 mL | 0.1058 mL | 0.2116 mL | 0.5290 mL |
VH032 Related Classifications
HY-120217 Related Classifications
Powered by Bioz